Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation

Nicoletta Cieri, Sara Mastaglio, Giacomo Oliveira, Monica Casucci, Attilio Bondanza, Chiara Bonini

Research output: Contribution to journalArticlepeer-review


Hematopoietic stem cell transplantation from a healthy donor (allo-HSCT) represents the most potent form of cellular adoptive immunotherapy to treat malignancies. In allo-HSCT, donor T cells are double edge-swords: highly potent against residual tumor cells, but potentially highly toxic, and responsible for graft versus host disease (GVHD), a major clinical complication of transplantation. Gene transfer technologies coupled with current knowledge on cancer immunology have generated a wide range of approaches aimed at fostering the immunological response to cancer cells, while avoiding or controlling GVHD. In this review, we discuss cell and gene therapy approaches currently tested in preclinical models and in clinical trials. Video podcast available: Go to to watch an interview with Guest Editor Dr Carl June.

Original languageEnglish
Pages (from-to)165-180
Number of pages16
JournalImmunological Reviews
Issue number1
Publication statusPublished - Jan 2014


  • Adoptive cellular immunotherapy
  • Allogeneic hematopoietic stem cell transplantation
  • CAR
  • Gene therapy
  • Suicide gene
  • TCR

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Cite this